Back to search
FDAFDA · Food and drugs·Recall number D-0388-2026

SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China

Published March 11, 2026 · Recall initiated: October 20, 2025

Summary

FDA records drug Class I recall D-0388-2026, published March 11, 2026 and initiated October 20, 2025. Recalling firm: ANTHONY TRINH, 123Herbals LLC; Status: Ongoing; Reported quantity: N/A; Lot: All lots within expiry. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ANTHONY TRINH, 123Herbals LLC
Distributor
USA nationwide
Lot
All lots within expiry
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China recalled?

Yes. FDA published recall D-0388-2026 on March 11, 2026. Reported hazard: Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release